Bioventus announced today that it has started selling Osteomatrix+ – a moldable bone graft substitute intended for a variety of orthopedic and spine bone remodeling applications.
Bioventus officials boast that Osteomatrix+ has improved moldability, flexibility and versatility versus its predecessor.
“Osteomatrix+ represents the first of several next-generation products that will be added to the Bioventus portfolio in the next five years,” Bioventus CEO Tony Bihl said in a news release.
Get the full story on our sister site Medical Design & Outsourcing.
The post Bioventus launches Osteomatrix+ bone graft appeared first on MassDevice.
from MassDevice http://bit.ly/2RO1Uqz
Cap comentari:
Publica un comentari a l'entrada